STAAR Surgical to Participate in Stephens Annual Investment Conference (NASH2024)
STAAR Surgical Company (NASDAQ: STAA) announces its participation in the upcoming Stephens Annual Investment Conference in Nashville. Chief Financial Officer Patrick F. Williams will participate in a webcast fireside chat on Wednesday, November 20, 2024, at 11:00 a.m. ET. STAAR Surgical, with over 40 years in ophthalmic surgery, specializes in developing implantable lenses, particularly the EVO ICL™ product line for myopia, astigmatism, and presbyopia. The company has sold more than 3,000,000 ICLs across 75+ countries and operates manufacturing facilities in California and Switzerland.
STAAR Surgical Company (NASDAQ: STAA) annuncia la sua partecipazione alla prossima Conferenza Annuale sugli Investimenti di Stephens a Nashville. Il Direttore Finanziario Patrick F. Williams parteciperà a una chiacchierata dal vivo via webcast mercoledì 20 novembre 2024, alle 11:00 a.m. ET. STAAR Surgical, con oltre 40 anni di esperienza nella chirurgia oftalmica, si specializza nello sviluppo di lenti impiantabili, in particolare della linea di prodotti EVO ICL™ per miopia, astigmatismo e presbiopia. L'azienda ha venduto più di 3.000.000 di ICL in oltre 75 paesi e gestisce stabilimenti di produzione in California e Svizzera.
STAAR Surgical Company (NASDAQ: STAA) anuncia su participación en la próxima Conferencia Anual de Inversiones de Stephens en Nashville. El Director Financiero Patrick F. Williams participará en un chat tipo 'fireside' a través de webcast el miércoles 20 de noviembre de 2024, a las 11:00 a.m. ET. STAAR Surgical, con más de 40 años de experiencia en cirugía oftálmica, se especializa en el desarrollo de lentes implantables, en particular de la línea de productos EVO ICL™ para miopía, astigmatismo y presbicia. La empresa ha vendido más de 3.000.000 de ICL en más de 75 países y opera instalaciones de fabricación en California y Suiza.
STAAR Surgical Company (NASDAQ: STAA)는 내슈빌에서 열리는 Stephens 연례 투자 컨퍼런스에 참가한다고 발표했습니다. 최고 재무 책임자 Patrick F. Williams는 2024년 11월 20일 수요일 오전 11시(ET)에 웹캐스트 화상 대화에 참석할 예정입니다. STAAR Surgical은 안과 수술 분야에서 40년 이상의 경험을 가지고 있으며, 특히 근시, 난시 및 노안을 위한 EVO ICL™ 제품 라인의 이식 가능한 렌즈 개발을 전문으로 하고 있습니다. 이 회사는 75개 이상의 국가에서 3,000,000개 이상의 ICL을 판매했으며, 캘리포니아와 스위스에 제조 시설을 운영하고 있습니다.
STAAR Surgical Company (NASDAQ: STAA) annonce sa participation à la prochaine Conférence Annuelle d'Investissement Stephens à Nashville. Le Directeur Financier Patrick F. Williams participera à une discussion en ligne mercredi 20 novembre 2024 à 11h00 ET. STAAR Surgical, avec plus de 40 ans d'expérience en chirurgie ophtalmique, se spécialise dans le développement de lentilles implantables, en particulier la ligne de produits EVO ICL™ pour la myopie, l'astigmatisme et la presbytie. L'entreprise a vendu plus de 3.000.000 ICL dans plus de 75 pays et possède des installations de fabrication en Californie et en Suisse.
STAAR Surgical Company (NASDAQ: STAA) gibt bekannt, dass sie an der bevorstehenden Stephens Jahreskonferenz für Investitionen in Nashville teilnehmen wird. Finanzvorstand Patrick F. Williams wird am Mittwoch, den 20. November 2024, um 11:00 Uhr ET an einem Online-Chat teilnehmen. STAAR Surgical hat über 40 Jahre Erfahrung in der Augenheilkunde und ist auf die Entwicklung von implantierbaren Linsen spezialisiert, insbesondere auf die Produktlinie EVO ICL™ für Kurzsichtigkeit, Astigmatismus und Presbyopie. Das Unternehmen hat mehr als 3.000.000 ICLs in über 75 Ländern verkauft und betreibt Produktionsstätten in Kalifornien und der Schweiz.
- None.
- None.
Event: Stephens Annual Investment Conference (NASH2024)
Management Attendee: Patrick F. Williams, Chief Financial Officer
Date: Wednesday, November 20, 2024
Time: 11:00 a.m. ET / 8:00 a.m. PT
Location: Live Webcast
The live webcast link includes an option to pre-register. An online replay of the webcast will also be available on STAAR’s investor website at https://investors.staar.com/.
About STAAR Surgical
STAAR, which has been dedicated solely to ophthalmic surgery for over 40 years, designs, develops, manufactures and markets implantable lenses for the eye. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR’s lens used in refractive surgery is called an Implantable Collamer® Lens or “ICL,” which includes the EVO ICL™ product line. More than 3,000,000 ICLs have been sold to date and STAAR markets these lenses in over 75 countries. To learn more about the ICL go to: EVOICL.com. Headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20241113681040/en/
Investors & Media
Brian Moore
Vice President, Investor Relations and Corporate Development
(626) 303-7902, Ext. 3023
bmoore@staar.com
Connie Johnson
Director, Investor Relations and HPMS
(626) 303-7902, Ext. 2207
cjohnson@staar.com
Source: STAAR Surgical Company
FAQ
When is STAAR Surgical (STAA) presenting at the Stephens Annual Investment Conference 2024?
How many ICL lenses has STAAR Surgical (STAA) sold globally?
Where are STAAR Surgical's (STAA) manufacturing facilities located?
What types of eye conditions does STAAR Surgical's (STAA) EVO ICL treat?
